# A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

> **NCT07079228** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 602 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** QLS31905
- **DRUG:** Nab-paclitaxel.
- **DRUG:** Gemcitabine
- **DRUG:** Placebo for QLS31905
- **DRUG:** Nab-paclitaxel.
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT07079228
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2028-12
- **Final completion:** 2030-09
- **Target enrollment:** 602 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079228, "A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07079228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*